Lanzotred Special Precautions

Risk of seizure: Use of enzalutamide has been associated with seizure. The decision to continue treatment in patients who develop seizure should be taken case by case.
Posterior Reversible Encephalopathy Syndrome: There have been rare reports of posterior reversible encephalopathy syndrome (PRES) in patients receiving Lanzotred. PRES is a rare, reversible, neurological disorder which can present with rapidly evolving symptoms including seizure, headache, confusion, blindness, and other visual and neurological disturbances, with or without associated hypertension. A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic resonance (MRI). Discontinuation of Lanzotred in patients who develop PRES is recommended.
Concomitant use with other medicinal products: Enzalutamide is a potent enzyme inducer and may lead to loss of efficacy of many commonly used medicinal products. A review of concomitant medicinal products should therefore be conducted when initiating enzalutamide treatment. Concomitant use of enzalutamide with medicinal products that are sensitive substrates of many metabolising enzymes or transporters should generally be avoided if their therapeutic effect is of large importance to the patient, and if dose adjustments cannot easily be performed based on monitoring of efficacy or plasma concentrations.
Co-administration with warfarin and coumarin-like anticoagulants should be avoided. If Lanzotred is co-administered with an anticoagulant metabolised by CYP2C9 (such as warfarin or acenocoumarol), additional International Normalised Ratio (INR) monitoring should be conducted.
Recent cardiovascular disease: There are no data of its use in patients with recent myocardial infarction (in the past 6 months) or unstable angina (in the past 3 months), New York Heart Association Class (NYHA) III or IV heart failure except if Left Ventricular Ejection Fraction (LVEF) ≥45%, bradycardia or uncontrolled hypertension. This should be taken into account if Lanzotred is prescribed in these patients.
Use with chemotherapy: The safety and efficacy of concomitant use of Lanzotred with cytotoxic chemotherapy has not been established. Co-administration of enzalutamide has no clinically relevant effect on the pharmacokinetics of intravenous docetaxel; however, an increase in the occurrence of docetaxel-induced neutropenia cannot be excluded.
Excipients: Lanzotred contains sorbitol (E420). Patients with rare hereditary problems of fructose intolerance should not take this medicinal product.
Hypersensitivity reactions: Hypersensitivity reactions manifested by symptoms including, but not limited to, rash, or face, tongue, lip, or pharyngeal oedema, have been observed with enzalutamide.
Effects on ability to drive and use machines: Enzalutamide may have moderate influence on the ability to drive and use machines as psychiatric and neurologic events including seizure have been reported. Patients should be advised of the potential risk of experiencing a psychiatric or neurological event while driving or operating machines. No studies to establish the effects of enzalutamide on the ability to drive and use machines have been conducted.
Renal impairment: Caution is required in patients with severe renal impairment as enzalutamide has not been studied in this patient population.
Severe hepatic impairment: An increased drug half-life has been observed in patients with severe hepatic impairment, possibly related to increased tissue distribution. The clinical relevance of this observation remains unknown. A prolonged time to reach steady state concentrations is however anticipated, and the time to maximum pharmacological effect as well as time for onset and decline of enzyme induction may be increased.